Oncology Venture Sweden AB announces approval of passportation of supplement to prospectus
Oncology Venture Sweden AB ("Oncology Venture") hereby announces approval of passportation of supplement to the prospectus. The Swedish Financial Supervisory Authority has issued an approval on passportation of Oncology Ventures supplement to the prospectus in Denmark. The English/Danish version of the supplement to the prospectus is available via the Company´s (www.oncologyventure.com), AktieTorget´s (www.aktietorget.se) and Sedermera Fondkommission´s (www.sedermera.se) respective websites.For further information about Oncology Venture, please contact: Ulla Hald Buhl, COO and or Peter